Navigation Links
Aisling Capital Announces Close of US$650M Life Sciences Fund
Date:1/7/2009

NEW YORK, Jan. 7 /PRNewswire/ -- Aisling Capital announced today that it raised US$650 million in committed capital for its newest life sciences fund, Aisling Capital III, LP. Aisling Capital will invest its third fund primarily in companies developing pharmaceutical, biopharmaceutical and medical products, as well as in businesses that provide drug development, manufacturing and other important services to the healthcare industry. With a total of over US$1.6 billion in committed capital under management, the Aisling Capital team will also continue to manage the Perseus-Soros BioPharmaceutical Fund, LP and Aisling Capital II, LP.

"We appreciate the support of our existing and new limited partners, particularly during these times of market turbulence," commented Dennis Purcell, Senior Managing Partner of Aisling Capital. Mr. Purcell added: "We believe the next several years will be a critical period for the life sciences industry, in which multiple forces will converge to create opportunities for the prepared investor."

The Aisling Capital team is comprised of individuals with a combination of clinical, transactional, operational and capital markets expertise, complemented by extensive networks in the life sciences industry. The team is led by Managing Partners Dennis Purcell, Steve Elms and Andrew Schiff, M.D. and newly promoted Partners Dov Goldstein, M.D., Anthony Sun, M.D. and Brett Zbar, M.D. Additionally, Josh Bilenker, M.D. has been promoted to Principal.

About Aisling Capital

Aisling Capital is a dedicated life sciences private equity firm with over US$1.6 billion under management. Headquartered in New York, Aisling Capital invests in both private and public companies utilizing a wide variety of investment structures. The Aisling Capital team's combination of clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life
'/>"/>

SOURCE Aisling Capital
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
2. Rigel to Participate at the RBC Capital Markets Healthcare Conference
3. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
4. Micromet to Present at the RBC Capital Markets Healthcare Conference
5. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
6. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
9. Medarex to Present at the RBC Capital Markets Healthcare Conference
10. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
11. Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 PuraMed BioScience ® ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... on the company based on low market capitalization ... Non-Prescription, All Natural Product to Treat Migraine Headaches ... #1 Prescription Competitor , Currently Available Nationwide ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... YORK, Oct. 23 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... notice from The,Nasdaq Stock Market ("Nasdaq") stating that ... a minimum bid price of,$1.00 per share, has ... the Company that it now has until January ...
... Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... abstract entitled "Phase I Trial,of Oncolytic Reovirus ... Advanced Solid Cancers" will be,available in the ... official journal of the International Society for ...
... Md., Oct. 23 MedImmune today announced,that researchers ... at the Annual Meeting of the American College ... the Moscone Center in San Francisco, California., ... solutions for patients,struggling with systemic autoimmune rheumatic diseases," ...
Cached Biology Technology:Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 3MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 2MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 3
(Date:5/22/2013)... Trial (NLST) investigators also conclude that the 20 ... computed tomography (LDCT) versus chest X-ray (CXR) screening ... achievable at experienced screening centers in the United ... share with their patients about the benefits and ... publication in the New England Journal of ...
(Date:5/22/2013)... that can detect molecular variants in chemical mixtures ... most important, though time-consuming, processes in analytical chemistry. ... , post-doctoral researcher David Patterson, Professor of Physics John ... Free-Electron Laser Science (CFEL) in Hamburg, Germany developed a ... molecular variants apart, and to determine how much variant ...
(Date:5/22/2013)... 2013)The omega 3 fatty acids in fish oil have ... so that the American Heart Association currently recommends eating ... fatty varieties rich in omega 3s. However, the mechanism ... a new study, scientists led by Jason R. Carter ... by providing evidence that fish oil might specifically counteract ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Detecting mirror molecules 2Detecting mirror molecules 3Fish oil may help the heart beat mental stress 2
... Foundation has granted two Clemson University professors $250,000 to ... 10 times smaller in diameter than a human hair ... both money and time compared to more traditional methods ... work like a sponge to draw up fluids from ...
... ESA and European industries have updated the planning of ... of 27 October 2008 for the GOCE satellite. ... GOCE from the Plesetsk Cosmodrome in northern Russia were ... one of the units of the guidance and navigation ...
... dinosaurs that perished in a catastrophic event 72.5 million ... frill on the back of the skull ornamented with ... their nose and eyes which lends them their name: ... keratin. According to Dr. Philip Currie, renowned palaeontologist ...
Cached Biology News:A new dinosaur species, Pachyrhinosaur lakustai, unveiled from Pipestone Creek, Alberta, Canada 2
CMRL Medium-1066 (1X) liquid...
... The PhosphatidylEthanolamine-Binding Protein (PEBP) does not ... protease inhibitors. PEBP is expressed ... testis, ovary, muscle, and stomach. ... in is exerting inhibitory activity against ...
karyopherin alpha2 (2G7)...
50 assays. Provides an easy system for rapid separation of cytosol and particulate fractions that are compatiable with downstream studies....
Biology Products: